These mechanistic data suggest a clinical pharmacologic strategy to counter the aggressive disease and poor clinical outcomes conferred by inheritance of the adrenal-permissive HSD3B1 allele, which commonly occurs in men with prostate cancer. Here, HSD3B1 is linked to Familial prostate cancer.